{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-103026","form_type":"8-K","ticker":"RARE","cik":"0001515673","company_name":"Ultragenyx Pharmaceutical Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.188311+00:00","generated_at":"2026-05-17T20:38:04.078032+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ultragenyx Q2 revenue $166M (+13% YoY); net loss narrows; UX111 BLA receives CRL","bullets":["Q2 total revenue $166M, Crysvita $120M, Dojolvi $23M; net loss $115M ($1.17/sh) vs $132M loss prior year.","Reaffirms 2025 guidance: total rev $640-670M, Crysvita $460-480M, Dojolvi $90-100M; path to profitability in 2027.","UX111 gene therapy for Sanfilippo type A received FDA CRL for CMC/manufacturing issues; clinical data package no issues; resubmission after Type A meeting.","GTX-102 for Angelman syndrome granted Breakthrough Therapy; Phase 3 Aspire fully enrolled (129 pts); data expected H2 2026.","UX143 Phase 3 final analysis expected end of 2025; DTX401 BLA submission planned Q4 2025; cash $539M as of June 30."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-103026","json":"https://secwatch.observer/filing/0000950170-25-103026.json","markdown":"https://secwatch.observer/filing/0000950170-25-103026.md","text":"https://secwatch.observer/filing/0000950170-25-103026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025103026/0000950170-25-103026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515673/000095017025103026/rare-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:38:04.078032+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}